key: cord-0284868-vfwjqj7l
authors: MALAVAZOS, A. E.; Basilico, S.; Iacobellis, G.; Milani, V.; Cardani, R.; Boniardi, F.; Dubini, C.; Prandoni, I.; Capitanio, G.; Renna, L. V.; Boveri, S.; Carrara, M.; Spuria, G.; Cuppone, M. T.; D'Acquisto, A.; Carpinelli, L.; Sacchi, M.; Morricone, L.; Secchi, F.; Costa, E.; Menicanti, L.; Nisoli, E.; Carruba, M. O.; Ambrogi, F.; Corsi Romanelli, M. M.
title: Antibody responses to BNT162b2 mRNA vaccine: infection-naive individuals with abdominal obesity warrant attention
date: 2021-09-14
journal: nan
DOI: 10.1101/2021.09.10.21262710
sha: 380a724b72f25f940042b821c7d4fb97bac68cd1
doc_id: 284868
cord_uid: vfwjqj7l

Objective. The excess of visceral adipose tissue might hinder and delay the immune response. How people with abdominal obesity will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2-specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals affected by abdominal obesity (AO) to those without, discerning between individuals with or without prior infection. Methods. IgG neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose-1, at one month and three months after dose-2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine abdominal obesity. Results. Between the first and third month after vaccine dose-2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p<0.001). Multiple linear regression confirmed this result even when adjusting for possible confounders (p<0.001). Conclusions. Our findings highlight the need to extend the duration of serological monitoring of antibody levels in infection-naive individuals with abdominal obesity, a higher-risk population category in terms of possible weaker antibody response.

Individuals with obesity and particularly those with predominant visceral adipose tissue (VAT) accumulation are at significant risk of developing a more severe coronavirus disease 2019 (COVID-19) [1] [2] [3] .

Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, hold great promise for curbing the spread of infection and accelerating the timeline towards a possible level of herd immunity [4] . Nevertheless, researchers fear that vaccines against SARS-CoV-2 might not be as effective in people with obesity [5] , since studies on vaccines against influenza, hepatitis B, and rabies have shown a reduced immune response in these individuals [5, 6] . To date, the available clinical evidence demonstrates that the efficacy of mRNA vaccines against SARS-CoV-2 does not differ among individuals with obesity compared to those without obesity [4, 7] .

However, these analyses have focused on the definition of obesity assessed through body mass index (BMI), yet this is not the best indicator of adiposity since it does not take into account the amount and distribution of body fat, which can differ broadly among people with the same BMI [8] . The excess of VAT is considered the main culprit in inflammatory diseases linked to obesity and it is an indicator of increased ectopic fat, which might hinder and delay the immune response, as highlighted by COVID-19 [1, 2, 5, [8] [9] [10] [11] . How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established.

To this end, we evaluated SARS-CoV-2-specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine in a large cohort of healthcare workers. We compared the response of individuals affected by AO to those without AO, discerning between individuals with, or without prior SARS-CoV-2 infection.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 14, 2021. ; We collected blood samples from a cohort of healthcare workers who received two doses of BNT162b2 mRNA vaccine at IRCCS Policlinico San Donato, a large academic medical centre in Milan, Italy. One thousand and sixty patients met the following inclusion criteria: (1) age >18 years; (2) two doses of BNT162b2 mRNA vaccine. Pregnancy was an exclusion criterion. All participants provided data on medical history, pharmacotherapy (if any), smoking status and symptoms if reported prior SARS-CoV-2 infection.

Anthropometric parameters were assessed at baseline. Waist circumference was measured midway between the lower rib and the iliac crest to the closest 1.0 cm. The cut-off to determine AO was 94 cm in men and 80 cm in women [8, 12] . BMI was calculated as weight (kilograms) divided by height (meters) square [13] .

Antibody levels were measured at four time points: at baseline, at day 21 after vaccine dose-1, at one month (within 30-40 days) and three months (within 90-100 days) after dose-2.

Serological testing for SARS-CoV-2 glycoprotein-specific anti-spike (S) IgG was performed using LIAISON® assay, which measures IgG neutralizing antibodies against the Trimeric complex (IgG-TrimericS), which includes the receptor-binding-domain (RBD) and N-terminal-domain (NTD) sites from the three S1 subunits. We used nucleocapsid (N) antibodies to detect prior infection. Given that the BNT162b2 vaccine delivers mRNA encoding only for S-protein, the expected elicited response is the production of IgG-TrimericS levels and not N-antibodies, which represent a durable marker and indicator of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 14, 2021. ;  post-infectious status [14] [15] [16] . Antibody assay methods are discussed in more detail in the supporting information. Results were reported as Binding Antibody Unit (BAU)/ml (≥33.8 BAU/ml is positive).

We expressed antibody levels as geometric mean (standard error, SE). Confidence intervals of the geometric means were calculated using log transformed data and t-tables with back-transformation. Individuals were categorized according to AO and BMI-classes with and without prior SARS-CoV-2 infection. For comparing between-group continuous values, the nonparametric Kruskal-Wallis test was used. We used multivariable linear regression to account for possible confounding and evaluate the three months difference in absolute variation of titre levels starting from one month after dose 2 in individuals with and without AO (or BMIclasses). The model was also adjusted for one month after dose 2 antibody levels, gender, age, smoke, prior

hypothesis will be refused with p<0.05. All statistical analyses were done with SAS version 9.4 (SAS Institute, Cary, NC).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 14, 2021. ;

Baseline characteristics of patients are reported in Table 1 . Vaccine recipients (n=1060), who provided at least three blood samples for antibody testing, were aged 41.4±12.9 years, 62% were female, and 93% were Analysis of these data by multivariable linear regression showed evidence of interaction between AO and SARS-CoV-2 infection (p=0.002) (table 2) . Specifically, AO is associated with a drop in absolute IgG-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

Our results showed that infection-naïve individuals with AO had lower antibody development over time compared to individuals without AO. They reached a lower antibody peak and they had a more significant drop in antibody levels at three months after dose-2, regardless of possible confounders.

It is worth noting that infection-naïve individuals with AO reached a lower antibody peak after dose-2 than individuals with AO and prior infection after a single vaccine dose. Recent studies showed that individuals with previous SARS-CoV-2 infection may have a superior humoral response after the first dose of BNT162b2 compared with uninfected individuals who were fully vaccinated with two doses of BNT162b2 [17, 18] . Furthermore, we have found that among individuals with prior infection those with AO had higher IgG-TrimericS levels than those without AO at baseline. These data are consistent with a recent paper in which it was observed that individuals with severe obesity and prior infection exhibited a higher neutralising antibody titre likely due to more severe COVID-19 [11] .

A recent small study, conducted over a period of only four weeks after vaccine dose-2, hypothesised that central obesity is associated with lower antibody titres following mRNA vaccines against SARS-CoV-2 [19].

The lower antibody response and its more significant drop over time, highlighted by classifying the population by AO phenotype rather than BMI-based obesity, can be explained in several ways, the most important being the greater chronic-inflammatory status due to an excess of abdominal VAT, which could compromise the immune system [1, 5, 6] .

Remarkably, the available clinical evidence and a recent position statement showed that vaccines are not less effective for individuals with obesity and that they are an important protection against COVID-19 [4, 7] . Antibody titre following SARS-CoV-2 vaccination cannot predict alone the risk of developing COVID-19, and even low antibody levels could be equally protective against infection. Moreover, in a recent pre-print study, it was shown that BNT162b2 mRNA vaccine efficacy tends to gradually decrease after six months, while maintaining a high safety profile [20].

Limitations of our study include lack of measurement of virus-specific T-cell. Anti-N antibodies were assessed only once to determine a prior SARS-CoV-2 infection. In addition, we did not evaluate proinflammatory markers of inflammation.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ;

Abdominal obesity (waist circumference ≥ 94 cm for men, ≥ 80cm for women); no abdominal obesity (waist circumference <94cm for men, <80cm for women). Antibody levels are expressed as BAU/ml (BAU = Binding Antibody Units) and are presented as geometric mean [confidence interval]. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 14, 2021. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 14, 2021. ;

Visceral Adiposity Elevates the Risk of Critical Condition in COVID-19: A Systematic Review and Meta-Analysis

Targeting the Adipose Tissue in COVID-19

COVID-19 Rise in Younger Adults with Obesity: Visceral Adiposity Can Predict the Risk. Obesity (Silver Spring)

Safety and Efficacy of the BNT162b2 mRNA Covid-19

How obesity could create problems for a COVID vaccine

The Impact of Obesity and Metabolic Syndrome on Vaccination Success

COVID-19 Vaccines are Effective in People with Obesity: A Position Statement from The Obesity Society

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

Epicardial fat inflammation response to COVID-19 therapies

Epicardial Fat Inflammation in Severe COVID-19

The Association Between Obesity and Peak Antibody Titer Response in COVID-19 Infection

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Underweight (BMI <18.5 kg/m 2 ); Normal weight (BMI from 18.5 to <25 kg/m 2 )

Overweight (BMI from 25 to <30 kg/m 2 )

Obesity (BMI≥30 kg/m 2 ). Body Mass Index (BMI)

Waist-toheight ratio (WHtR)

Antibody levels are expressed as BAU/ml (BAU = Binding Antibody Units) and are presented as geometric mean

To compare variables between different groups, the Chi-square or *Fisher's exact test was used for categorical variables. T-test or Wilcoxon rank sum test is used to compare unpaired means in normally or non-normally continuous distributed variables, respectively. § n total=1060